ReviewAsian journal of andrology2012
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.
Review in Asian journal of andrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.Contrast media & molecular imaging · 2018Trial
- Electrochemical Detection of Prostate Cancer-Associated miRNA-141 Using a Low-Cost Disposable Biosensor.Biosensors · 2025Article
- Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics ofCPT: pharmacometrics & systems pharmacology · 2023Article
- Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.Exploration of targeted anti-tumor therapy · 2023Review
- Ambient air pollution and prostate cancer risk in a population-based Canadian case-control study.Environmental epidemiology (Philadelphia, Pa.) · 2022Article
- Evaluation ofReports of biochemistry & molecular biology · 2021Article
- Article
- Article
- Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.The Prostate · 2015Article
- Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancer.Urology · 2015Article
- Active surveillance in patients with a PSA >10 ng/mL.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2014Article
- Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.Clinical biochemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.